Earnings Feed
Start Free
Home/Filings/4/0001246360-15-001488
4//SEC Filing

SYNAGEVA BIOPHARMA CORP 4

Accession 0001246360-15-001488

CIK 0000911326operating
View on SEC.govCompany Profile

Filed

Mar 12, 8:00 PM ET

Accepted

Mar 13, 5:49 PM ET

Size

20.6 KB

Accession

0001246360-15-001488

Insider Transaction Report

Form 4
Period: 2015-03-11
SYNAGEVA BIOPHARMA CORPGEVA
Heberlig Chris
Vice President, Finance
Transactions
  • Award

    Common Stock

    2015-03-11$76.88/sh+86$6,612→ 390 total
  • Exercise/Conversion

    Common Stock

    2015-03-11$40.74/sh+7,500$305,550→ 7,890 total
  • Sale

    Common Stock

    2015-03-11$100.44/sh−900$90,396→ 6,990 total
  • Sale

    Common Stock

    2015-03-11$104.57/sh−1,510$157,901→ 690 total
  • Sale

    Common Stock

    2015-03-11$105.74/sh−300$31,722→ 390 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-03-11−7,500→ 7,500 total
    Exercise: $40.74Exp: 2022-06-27→ Common Stock (7,500 underlying)
  • Sale

    Common Stock

    2015-03-11$102.46/sh−900$92,214→ 5,490 total
  • Sale

    Common Stock

    2015-03-11$103.55/sh−3,290$340,680→ 2,200 total
  • Sale

    Common Stock

    2015-03-11$101.38/sh−600$60,828→ 6,390 total
Footnotes (11)
  • [F1]The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Synageva BioPharma Corp. Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2014 through December 31, 2014. This transaction is also exempt under Rule 16b-3(c).
  • [F10]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $104.15 to $105.00. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  • [F11]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $105.59 to $106.01. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  • [F2]The reporting person is voluntarily reporting this transaction as of 03/11/2015, but the actual transaction took place on 12/31/2014, the last trading day of the option period under the ESPP.
  • [F3]In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on July 1, 2014, the first trading day of the option period.
  • [F4]The stock option exercise and sale of shares of the Company's common stock (the "Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 3, 2014.
  • [F5]The Stock Option granted the reporting person an option to purchase 15,000 Shares. 25% of such Shares vested and became exercisable on 06/27/2013, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
  • [F6]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $100.10 to $100.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  • [F7]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.12 to $101.88. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  • [F8]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.98 to $102.94. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  • [F9]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $103.00 to $103.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Documents

1 file

Issuer

SYNAGEVA BIOPHARMA CORP

CIK 0000911326

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000911326

Filing Metadata

Form type
4
Filed
Mar 12, 8:00 PM ET
Accepted
Mar 13, 5:49 PM ET
Size
20.6 KB
View on SEC.gov